<PAGE>
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant /X/
Filed by a party other than the Registrant / /
Check the appropriate box:
/ / Preliminary Proxy Statement
/ / Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
/ / Definitive Proxy Statement
/X/ Definitive Additional Materials
/ / Soliciting Material Pursuant to Section 240.14a-12
Genzyme Corporation
--------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
--------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
/X/ No fee required
/ / Fee computed on table below per Exchange Act Rules 14a-6(i)(1)
and 0-11
(1) Title of each class of securities to which transaction applies:
------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
------------------------------------------------------------------------
(5) Total fee paid:
------------------------------------------------------------------------
/ / Fee paid previously with preliminary materials.
/ / Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
------------------------------------------------------------------------
(3) Filing Party:
------------------------------------------------------------------------
(4) Date Filed:
------------------------------------------------------------------------
<PAGE>
[LOGO] GENZYME CORPORATION
ONE KENDALL SQUARE
CAMBRIDGE, MA 02139-1562, U.S.A.
617-252-7500
FAX 617-252-7600
NOTICE
ANNUAL MEETING OF SHAREHOLDERS
HAS BEEN ADJOURNED
NEW MEETING DATE: JUNE 20, 2000
TIME: 2:00 P.M.
PLACE: GENZYME CORPORATION
ONE KENDALL SQUARE
CAMBRIDGE, MA 02139
May 30, 2000
Dear Stockholder,
We have previously sent you material relating to the Annual Meeting
of Stockholders of Genzyme Corporation, that was held on May 25, 2000. The
meeting has been adjourned until Tuesday, June 20, 2000 in order to allow
sufficient time to obtain the additional voting needed to pass the third
proposal submitted for your approval.
This proposal is an amendment to our corporate charter to modify the
terms of the Genzyme Molecular Oncology, Genzyme Surgical Products and Genzyme
Tissue Repair common stock. The required vote to pass the amendment for each
series of stock is a majority of the outstanding shares for that series. Without
specific voting instructions from you, your broker can not vote your shares for
you on this proposal.
Your vote is urgently needed to avoid the continued expense of
additional solicitations on this proposal. Please sign, date and mail the
enclosed proxy card today using the enclosed postage paid envelope provided. For
your convenience, if you have internet access, you may vote online at our proxy
voting web site, http://www.eproxyview.com/genz. You may vote from this web site
regardless of which series of stock you own. You will need the control number
from your ballot form to properly register your vote online.
We appreciate your cooperation in this matter.
By Order of the Board of Directors
PETER WIRTH, CLERK
